KROS - Keros Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

1.46B

Cash

442.4M

Avg Qtr Burn

-33.71M

Short % of Float

9.27%

Insider Ownership

6.10%

Institutional Own.

-

Qtr Updated

03/31/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
KER-050 (elritercept) Details Blood cancer, Cystic fibrosis, Lung disease, Myelofibrosis, Cancer	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
KER-012 (cibotercept) Details Pulmonary hypertension, Cardiovascular disease	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
KER-050 (elritercept) Details Blood disorder, Cancer, Myelodysplastic syndrome	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
KER-065 Details Duchenne muscular dystrophy, Neuromuscular disease	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
KER-065 Details Obesity	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
KER-047 (ALK2 inhibitor) Details Myelodysplastic syndrome, Myelofibrosis	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
KER-047 (ALK2 inhibitor) Details Fibrodysplasia ossificans progressiva, Anemia	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.